Prostate Cancer Risk Assessment Using Genetic Markers in General Practice

Condition: Prostate Cancer

Intervention:

• Genetic: Genetic risk assessment

Purpose: The preferred method for early detection of prostate cancer (PCa) in older men with family history is the Prostate Specific Antigen test (PSA test), although the method is imprecise. It produces a high number of false-positive results and increases the risk of over-diagnosis and over-treatment. Yet, an increasing number of men get the PSA test as part of unsystematic screening. Genetic risk assessment may be a better way to identify men with low risk of PCa. The main study hypothesis is that genetic information about low risk of PCa can reduce the number of patients who get a PSA test as part of unsystematic screening.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT01739062

Sponsor: University of Aarhus

Primary Outcome Measures:

• Measure: Number of low risk patients who get a PSA test
• Time Frame: 1 year, 2 years
• Safety Issue:

Estimated Enrollment: 5000

Study Start Date: February 2013

Eligibility:

• Age: minimum 18 Years maximum 80 Years
• Gender: Male

Inclusion Criteria:

• patients who receive a PSA test

Exclusion Criteria:

• age over 80 years
• elevated PSA-level (> 4,0 ng/ml) concurrently or within previous 2 years
• prostate or bladder disease
• prostate cancer
• non-Caucasians
• do not speak and understand Danish

Contact:

• Karina D Sørensen, PhD
• 78455316 Ext. 0045

Location:

• Department of Molecular Medicine
• Aarhus N Aarhus 8200 Denmark

View trial on ClinicalTrials.gov